Eckert | Jotup

EQS-News: Eckert & Ziegler Receives Award for Professional Training

Retrieved on:

Thursday, September 28, 2023

Human resources, Australian Training Awards, Federal Executive Boards, Eckert, Nursing

Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality.

Key Points:

Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality.
The jury justified the award with the great commitment to professional training and the special training concept of Eckert & Ziegler AG.
Applications are gladly accepted at any time.The Berlin-Pankow Training Prize is awarded annually as part of the Pankow Training Initiative to particularly committed training companies in the Pankow district.
Eckert & Ziegler receives the Pankow 2023 Training Award in the category with over 50 employees.

Federal Court Order Removes Confidential Designation on Emails Related to Eckert Seamans Cherin & Mellott’s Involvement in Efforts to “Kill Skill” Games

Retrieved on:

Tuesday, September 5, 2023

Parx Casino and Racing, NOT, Pennsylvania Gaming Control Board, Law enforcement, FINDS, Doc, Confidentiality, Government, Barley, VFW-Fokker 614, Motion, American Legion, Commonwealth, Eckert, POM

“The efforts by Eckert Seamans, Parx Casino and others to work behind the scenes to use the levers of government to go after skill games must be exposed.

Key Points:

“The efforts by Eckert Seamans, Parx Casino and others to work behind the scenes to use the levers of government to go after skill games must be exposed.
Some exhibits include email correspondence between Defendant Stewart and Parx Casino employees, non-party attorneys, or other non-parties.
The court DECLARES that these documents DO NOT QUALIFY AS CONFIDENTIAL.”
Click here to read the full order.
Barley concluded, “Despite the failed, and soon to be further exposed, efforts of Eckert Seamans, Parx and others to ‘kill skill’ – as they wrote in emails -- we believe the will of the legislature is clear… regulate and tax skill games.

Pace-O-Matic Granted Access to Eckert Seamans Privileged Logs

Retrieved on:

Monday, June 26, 2023

The suit also alleges that Eckert “violated their most basic fiduciary duties and concealed and misrepresented material facts to POM’s great detriment.

Key Points:

The suit also alleges that Eckert “violated their most basic fiduciary duties and concealed and misrepresented material facts to POM’s great detriment.
In November 2021, US Magistrate Judge Joseph Saporito, Jr. found that Eckert acted in “bad faith” by seeking to withhold emails that demonstrated Eckert was representing both sides.
Eckert, Saporito ruled, “actively and clandestinely managed and participated in the representation of Parx in the Commonwealth Court litigation against its other client, POM.
Eckert appealed Jude Saporito’s ruling, which required Eckert to turn over to POM many internal emails.

EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma

Retrieved on:

Saturday, June 10, 2023

Lymphoma, PMID, Medical device, CXCR4, BFS, TecDAX, CNS, Teaching hospital, Radioligand, University Hospital (Newark, New Jersey), DOI, ISIN, Yttrium, T-cell lymphoma, Eckert, Safety, Pharmaceutical industry, Patient

The Yttrium-90 labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic against recurrent or refractory primary or isolated secondary central nervous system lymphoma.

Key Points:

The Yttrium-90 labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic against recurrent or refractory primary or isolated secondary central nervous system lymphoma.
The phase I/II, dose-finding study will be conducted at the University Hospital in Essen, North Rhine Westphalia, Germany.
The study will start after getting final endorsement from the German Radiation Safety Department (BfS),“ commented Dr. Hakim Bouterfa, Chief Medical Officer at Eckert & Ziegler.
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

Retrieved on:

Tuesday, May 9, 2023

Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.

Key Points:

Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.
It would most likely have a large impact on clinical practice and enable a large number of hypertension patients to be cured.
The study in Australia is in line with clinical activities in Europe and in the USA, which are supported by PentixaPharm.
[68Ga]Ga-PentixaFor is being developed by Eckert & Ziegler's subsidiary PentixaPharm GmbH also as a superiorly sensitive diagnostic for a portfolio of hematooncological malignancies.

EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

Retrieved on:

Thursday, April 20, 2023

GMP, Medicine, Glomus tumor, TecDAX, PET, Radiopharmaceutical, Federal Executive Boards, ISIN, DMF, Eckert, Prostate cancer, Medical imaging, Lutetium

Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority.

Key Points:

Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority.
The approval is the basis for the marketing authorization of Lutetium-177 as a drug, but also for use of this radioisotope as a starting material for the manufacture of radiopharmaceuticals.
By making Lutetium available to a significantly broader range of users, the approval will enable Eckert & Ziegler to further continue its successful strategy as one of the world leading isotope suppliers.
The beta emitting Lutetium-177 is linked to a tumor specific ligand which then targets the tumor cells to destroy them.

EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

Retrieved on:

Friday, March 3, 2023

DMF, Isotope, Type, RTÉ Executive Board, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eckert, Radiopharmaceutical, ISIN, Ytterbium, CMC, SDAX, Food, Lutetium, Pharmaceutical industry, Medical imaging

Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

Key Points:

Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043.
"We are excited about the access to the U.S. market for lutetium-177 based radiotherapeutics," explains Dr. Lutz Helmke, member of the Executive Board and responsible for the Medical segment at Eckert & Ziegler.
Radionuclide therapy with lutetium-177, is becoming well established as a valuable treatment option within precision oncology for various indications.

Greenwood Gaming, Parx Casino Bring Baseless Lawsuit Against Pace-O-Matic and Pennsylvania Small Businesses & Fraternal Clubs Operating Legal Skill Games

Retrieved on:

Thursday, October 27, 2022

Duluth, GA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Pace-O-Matic (POM), a gaming company that does significant business throughout Pennsylvania, today released the following statement in response to a baseless lawsuit brought by Greenwood Gaming and Parx Casino against POM and thousands of small businesses and fraternal clubs operating skill games across the state.

Key Points:

Duluth, GA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Pace-O-Matic (POM), a gaming company that does significant business throughout Pennsylvania, today released the following statement in response to a baseless lawsuit brought by Greenwood Gaming and Parx Casino against POM and thousands of small businesses and fraternal clubs operating skill games across the state.
The lawsuit against legal skill games launched by Parx Casino and Greenwood Gaming is meritless and attacks thousands of Pennsylvania businesses who operate skill games and rely on their revenue.
We feel confident, as we always have, in the legal status of our skill games.
Parx Casino is attempting to shield its efforts, through various consultants, and use the levers of government to harm legal skill games, and in particular POMs Pennsylvania Skill games.

Pace-O-Matic Announces Major Fraud Suit Against Prominent Pennsylvania Law Firm

Retrieved on:

Monday, July 11, 2022

Duluth, GA, July 11, 2022 (GLOBE NEWSWIRE) -- Pace-O-Matic (POM), a Georgia-based gaming company that does significant business throughout Pennsylvania, today announced a major fraud claim against one of Pennsylvanias most prestigious law firms.

Key Points:

Duluth, GA, July 11, 2022 (GLOBE NEWSWIRE) -- Pace-O-Matic (POM), a Georgia-based gaming company that does significant business throughout Pennsylvania, today announced a major fraud claim against one of Pennsylvanias most prestigious law firms.
Make no mistake about it, Eckert engaged in an egregious conflict of interest where they unethically pitted one client against another, said Michael Barley, POMs Chief Public Affairs Officer.
Eckert is a major law firm that has more than 300 lawyers across a network of 15 offices, including Philadelphia, Harrisburg, Pittsburgh, Boston, Washington, DC, and Richmond, VA.
Parx Casinocalls itself the #1 casino in Pennsylvania and is owned and operated byGreenwood Racing Inc.
Eckert, working at the behest of Parx Casino and its consultants, sought to block Pace-O-Matic from doing business in Pennsylvania.

DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

Retrieved on:

Wednesday, July 6, 2022

Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.

Key Points:

Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.
The agreement covers the development of a validated manufacturing process as well as the GMP-compliant production of clinical investigational products.
Ratio Therapeutics will use the newly built GMP suites at the Eckert & Ziegler production site near Boston, MA, USA, from July 2022 for this purpose.
As a radiopharmaceutical contract manufacturer, Eckert & Ziegler is able to produce small batches for Phase I, II and III clinical studies and large commercially applicable batch sizes.